GSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow GSK
GSK PLC Sponsored ADR (GSK) EV/Sales
As of 16 October 2026, GSK PLC Sponsored ADR (GSK) trades at a EV/Sales of 2.7×. Over the past ten years it has ranged from 1.6× (September 2022) to 3.4× (December 2019); the current reading is higher than 70% of that period. That is below the Drug Manufacturers General industry median of 4.0× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.7× | 28.45% |
| FY2024 | 2.1× | (12.33%) |
| FY2023 | 2.4× | 1.43% |
| FY2022 | 2.4× | (2.36%) |
| FY2021 | 2.5× | 7.88% |
| FY2020 | 2.3× | (21.64%) |
| FY2019 | 2.9× | 14.59% |
| FY2018 | 2.5× | 10.80% |
| FY2017 | 2.3× | (8.45%) |
| FY2016 | 2.5× | (2.81%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.8× | (6.28%) |
| Mar 2026 | 3.0× | 9.70% |
| Dec 2025 | 2.7× | 8.30% |
| Sep 2025 | 2.5× | 7.78% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi compare | 2.0× |
| GSK GSK PLC Sponsored ADR | 2.7× |
| BMY Bristol Myers Squibb Company compare | 3.1× |
| PFE Pfizer Inc. compare | 3.5× |
| NVO Novo Nordisk A/S compare | 3.6× |
| AZN AstraZeneca PLC compare | 4.6× |
| NVS Novartis AG compare | 5.8× |
| GILD Gilead Sciences, Inc. compare | 7.1× |
| AMGN Amgen Inc. compare | 7.3× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)